Effectiveness and safety of upadacitinib in patients with moderate-to-severe atopic dermatitis and prior inefficacy of T helper 2 biologics: a propensity score-matched study
Rattachement africain : it, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Real-world data comparing patients with atopic dermatitis (AD) initially treated with upadacitinib vs. those previously treated with biologics or other Janus kinase inhibitors are limited. OBJECTIVES: To assess clinical outcomes over 52 weeks of treatment with upadacitinib and to compare patients treated with upadacitinib who had previously received T helper 2 (Th2) biologics but discontinued treatment owing to lack of efficacy (group A) with those who were bio-naive or had discontinued these treatments for reasons other than inefficacy (group B). METHODS: We conducted a retrospective multicentre study of 524 patients with moderate-to-severe AD treated with upadacitinib. A propensity score-matching method was used for the subanalysis of 316 patients to compare group A and group B. RESULTS: A significant clinical improvement starting from week 4 and continuing throughout the study period was observed in the overall population and in both groups A and B. Group B showed greater improvements at later follow-up times, with a higher median Eczema Area and Severity Index (EASI) percentage improvement at week 52 (P = 0.03) and a significantly higher proportion of patients achieving EASI 90 and EASI 100 (representing a ≥ 90% and 100% improvement from baseline, respectively) at week 36 (P =0.02, χ² = 9.5). For the Pruritus Numerical Rating Scale (P-NRS) and Sleep Disturbances Numerical Rating Scale (SD-NRS), group B had a significantly greater percentage of patients reporting a score of 0 or 1 at week 52 (P-NRS: P = 0.02, χ² = 5.7; SD-NRS: P = 0.049, χ² = 3.9). Group B also had a significantly higher percentage of patients reaching minimal disease activity at week 52 (P = 0.01, χ² = 6.0). CONCLUSIONS: Upadacitinib proved to be effective in the long term not only as a first-line therapy but also in patients with a history of treatment with a biologic that had been unsuccessful. However, patients in group B consistently demonstrated better clinical responses at later follow-ups, suggesting that individuals who are bio-naive and those who discontinued Th2 biologics for reasons other than inefficacy may respond more favourably to upadacitinib.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Effectiveness and safety of upadacitinib in patients with moderate-to-severe atopic dermatitis and prior inefficacy of T helper 2 biologics: a propensity score-matched study
- Date Crossref
- 11/06/2025
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Dermatology Unit pays non établi dans la noticeÉtablissement de santé
-
University of Milan pays non établi dans la noticeUniversité ou école supérieure
-
IRCCS Humanitas Research Hospital Dermatology Unit pays non établi dans la noticeÉtablissement de santé
-
IRCCS Policlinico San Donato pays non établi dans la noticeÉtablissement de santé
-
University of Verona Department of Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Ospedale San Bortolo pays non établi dans la noticeÉtablissement de santé
-
Azienda Ospedaliera Ospedali Riuniti Papardo Piemonte pays non établi dans la noticeÉtablissement de santé
-
University of Florence Department of Health Sciences pays non établi dans la noticeUniversité ou école supérieure
-
Università degli Studi del Piemonte Orientale “Amedeo Avogadro” pays non établi dans la noticeUniversité ou école supérieure
-
Piedmont University pays non établi dans la noticeUniversité ou école supérieure
-
Azienda Ospedaliero Universitaria Maggiore della Carita pays non établi dans la noticeÉtablissement de santé
-
Polyclinic Medical Center pays non établi dans la noticeÉtablissement de santé
Dermatology Unit — Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan et Dermatology Unit — IRCCS Humanitas Research Hospital, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.